June 24th 2025
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
February 17th 2025
Catalent, Ethicann Partner on Fast-Dissolve Cannabinoid Treatment for MS Spasticity
December 5th 2019Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.
Improving the Patient Experience with High Viscosity/High Volume Drugs
October 17th 2019On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.